Free Trial

Evan David Analyst Performance

Analyst at BMO Capital Markets

Evan David is a stock analyst at BMO Capital Markets in the medical sector, covering 2 publicly traded companies. Over the past year, Evan David has issued 2 stock ratings, including and buy recommendations. While full access to Evan David's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Evan David's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
2 Last 0 Years
Buy Recommendations
100.00% 2 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%2 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NYSE
50.0% of companies on NYSE
1 company
NASDAQ
50.0% of companies on NASDAQ
1 company

Evan David, an analyst at BMO Capital Markets, currently covers 2 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
100.0%

Evan David of BMO Capital Markets specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
LARGE CAP PHARMA
1 company
50.0%
MED - BIOMED/GENE
1 company
50.0%

Evan David's Ratings History at BMO Capital Markets

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
AbbVie Inc. stock logo
ABBV
AbbVie
9/12/2025Boost Price Target$220.09$240.00Outperform
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
8/4/2025Boost Price Target$567.14$640.00Outperform